Abstract 233P
Background
Protein polybromo-1 (PB1) encoded by the PBRM1 gene is involved in chromatin-remodeling processes as a part of the SWI/SNF complex. Pathogenic variants of PBRM1 gene are commonly encountered in ccRCC. Much attention has been drawn to the predictive potential of PBRM1 to immunotherapeutic agents’ response in solid tumors. This work aims to establish an interconnection between PBRM1 loss and TIME of ccRCC.
Methods
The ccRCC cohort was obtained from the Cancer Genome Atlas Program (TCGA). Patients were stratified based on the presence of PBRM1 pathological variants into wild type group (n = 213) or mutant group (n = 153). TIME was evaluated through the enrichment of immunological processes-related gene sets using gene set enrichment analysis (GSEA) within the hallmarks of cancer and ontology gene sets. A gene set was considered significantly enriched with a P-value < .05 and a false discovery rate (FDR) ≤ 0.25. Immune cells infiltration was explored using precalculated infiltration scores of xCell. T-cell dysfunction score was obtained from TIDE server.
Results
GSEA illustrated enrichments in three immunological sets within the hallmarks of cancer, including TNF-α signaling through NF-κB (enrichment score (ES) = 0.43, Q value < .001, FDR = 0.007), INF-α response (ES = 0.34, Q value = .03, FDR = 0.190), and INF-γ response (ES = 0.39, Q value < .001, FDR = 0.022). Gene ontology sets screening highlighted the effect of PBRM1 loss on CXCR chemokine receptor binding (ES = 0.75, Q value < .001, FDR = 0.202) with no enriched sets within the cellular component or biological process sections. The mutant group showed a significant CD8+ T-cells depletion alongside reduced infiltration of eosinophils, cancer-associated fibroblasts, M1 macrophages, and T helper 2 cells. PBRM1 damage did not induce a T-cell dysfunction (z score = 0.726, P = .468). In addition, PBRM1 loss was correlated with a superior response to nivolumab in a cohort of 35 patients (fold change = 58.7 and P = .0123).
Conclusions
PBRM1 Loss induces global transcription alternations that impact many immunological processes. Such phenomena could be associated with the positive correlation to immunotherapy response in ccRCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
613P - Differences in the interactions with pharmaceutical companies between medical oncologists and infectious diseases physicians
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
614P - The role of PD-L1 expression in prognosis of osteosarcoma patients: A systematic review and meta-analysis
Presenter: Alexander Purnomo
Session: Poster Display
Resources:
Abstract
615P - Pulmonary resectable metastases of osteosarcoma with apatinib and chemotherapy (PROACH): An open-label, single-arm phase II clinical trial
Presenter: Qiyuan Bao
Session: Poster Display
Resources:
Abstract
616P - Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis
Presenter: Paula Franco
Session: Poster Display
Resources:
Abstract
617P - The risk of acute myeloid leukaemia in patients with Ewing's sarcoma and trend analysis: A SEER-based study 2000-2020
Presenter: Mohamed Abdalla
Session: Poster Display
Resources:
Abstract
618P - Adult renal Ewing’s sarcoma/primitive neuroectodermal tumor: A 20-year retrospective review of molecular histopathological profiles, and clinical outcomes
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
619P - Single-cell and bulk RNA-seq analyses decode the renal microenvironment induced by polystyrene microplastics in mice receiving high-fat diet
Presenter: Wangrui Liu
Session: Poster Display
Resources:
Abstract
620P - A unique circulating microRNA pairs signature serves as a superior tool for early diagnosis of pan-cancer
Presenter: Dongyu Li
Session: Poster Display
Resources:
Abstract
621P - Effective identification of primary liver cancer from cirrhosis or chronic hepatitis virus infection using eight methylated plasma DNA markers: Marker discovery, phase I pilot, and phase II clinical validation
Presenter: Tian Yang
Session: Poster Display
Resources:
Abstract
622P - A prognostic and immune infiltration analysis of CCL26 in pan-cancer
Presenter: Mengyue Li
Session: Poster Display
Resources:
Abstract